The United States Anti-Doping Agency (USADA) announced today that Peter Cannell, an athlete in the sport of cycling, has accepted a two-year suspension for violating the applicable sport anti-doping rules, including the Union Cycliste Internationale (“UCI”) Rules and the World Anti-Doping Code (“Code”). Mr. Cannell’s anti-doping rule violation was based on the presence of the anabolic agent, drostanolone, in his urine sample collected as part of the USADA out of competition testing program on April 16, 2010.
Cannell, 37, of Mebane, North Carolina, accepted a two-year period of ineligibility for his doping offense, beginning on May 17, 2010, the day he accepted a provisional suspension. Through the course of an investigation into the case conducted by USADA, Mr. Cannell also acknowledged his previous use of an anabolic agent, and therefore all of Cannell’s competitive results will be disqualified, including forfeiture of all medals, points, and prizes since February 6, 2007.
In an effort to aid athletes, as well as all support team members such as parents and coaches, in understanding the rules applicable to them, USADA provides comprehensive instruction on its website on the testing process and prohibited substances, how to obtain permission to use a necessary medication, and the risks and dangers of taking supplements as well as performance-enhancing and recreational drugs. In addition, the agency manages a drug reference hotline, Drug Reference Online (www.GlobalDRO.com), conducts educational sessions with National Governing Bodies and their athletes, and proactively distributes a multitude of educational materials, such as the Prohibited List, easy-reference wallet cards, periodic newsletters, and protocol and policy reference documentation.
USADA is responsible for the testing and results management process for athletes in the U.S. Olympic and Paralympic Movement, and is equally dedicated to preserving the integrity of sport through research initiatives and educational programs.
For more information or media inquiries, click here.